Amelioration of microvascular myocardial ischemia by gene transfer of vascular endothelial growth factor in rabbits

Tanaka, Etsuro; Hattan, Naoichiro; Ando, Kiyoshi; Ueno, Hikaru; Sugio, Yoshinori; Mohammed, Minhaz Uddin; Voltchikhina, Svetlana A.; Mori, Hiromu

doi:10.1067/mtc.2000.109536

Cited by 22 publications

(16 citation statements)

References 26 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Non-transmural patchy myocardial infarction (MI) was created in 24 rabbits by microsphere injection (15 μm in diameter, 5 × 10 5 /mL, 3 mL) into the coronary arteries by the transcatheter approach introduced from the carotid arteries [7]. The remaining 24 rabbits served as controls.…”

Section: Animal Model and Heavy Ion Radiationmentioning

confidence: 99%

Heavy ion radiation up-regulates Cx43 and ameliorates arrhythmogenic substrates in hearts after myocardial infarction

Amino

Yoshioka

Tanabe

et al. 2006

Cardiovascular Research

View full text Add to dashboard Cite

show abstract

Section: Animal Model and Heavy Ion Radiationmentioning

confidence: 99%

Heavy ion radiation up-regulates Cx43 and ameliorates arrhythmogenic substrates in hearts after myocardial infarction

Amino

Yoshioka

Tanabe

et al. 2006

Cardiovascular Research

View full text Add to dashboard Cite

show abstract

“…In vivo, myocardial expression of VEGF-A is significantly augmented by ischemia or hypoxia and stretch [23]. Once VEGF-A increased, this factor is beneficial to the ischemic region as a therapeutic agent promoting collateral formation, indicating that VEGF-A exerts a potent effect on angiogenic response in cardiovascular disease [27]. Although the VEGF has been related to some hypertrophic processes [26], nothing is known about VEGF in hyperthyroidisminduced hypertrophy.…”

Section: Introductionmentioning

confidence: 98%

Early cardiac hypertrophy induced by thyroxine is accompanied by an increase in VEGF-A expression but not by an increase in capillary density

et al. 2006

View full text Add to dashboard Cite

Cardiac hypertrophy in response to hyperthyroidism is well known. However, the effects on cardiac microcirculation are still controversial in this model. The present study evaluated the effects of acute administration of two different thyroxine (T4) dose levels on the angiogenic response in the myocardium. Capillary density (CD), the CD to fiber density (FD) ratio (CD/FD), and intercapillary distance (ICD) were assessed, as was ventricle weight (VW) to body weight (BW) ratio (VW/BW). Collagen I and III messenger ribonucleic acid (mRNA) expression and VEGF-A expression were also determined by reverse transcriptase polymerase chain reaction (RT-PCR). Immunohistochemical detection of proliferating cell nuclear antigen (PCNA) expression in endothelial cell nuclei was also carried out. We simulated an acute hyperthyroidism situation in male Wistar rats by daily intraperitoneal injection of T4 (0.025 or 0.1 mg kg(-1) day(-1)) for 7 days. Hemodynamic parameters showed that T4 did not alter systolic blood pressure (SBP) but significantly increased heart rate (HR). Both T4 doses significantly increased VW. Morphologically, the higher T4 dose resulted in a 33% greater myocardial mass, which was not accompanied by alterations in collagen I and III mRNA expression. The CD and CD/FD parameters were significantly lower in the hyperthyroid rats treated with the higher dose than in the control animals, and PCNA-labeling analysis indicated total absence of marked capillary growth. However, although the acute treatment with T4 did not induce any alteration in capillary number and endothelial cell proliferation, the vascular endothelial growth factor (VEGF)-A mRNA and protein expression were significantly increased with the higher T4 dose. These data indicate that the cardiac hypertrophy induced by acute treatment with thyroid hormone precedes the angiogenic process, which probably occurs later.

show abstract

“…Results emanating from animal studies have shown that therapeutic angiogenesis by protein administration, non-viral, or viral vector implantation, has demonstrated promise. [1][2][3][4] More recently, clinical trials have demonstrated the safety and feasibility of the procedure. [5][6][7] Vascular endothelial growth factor (VEGF) is one of the well-studied factors for therapeutic angiogenesis for cardiac repair.…”

mentioning

confidence: 99%

In Vitro Functional Assessment of Human Skeletal Myoblasts After Transduction With Adenoviral Bicistronic Vector Carrying Human VEGF165 and Angiopoietin-1

Haider

Jiang

et al. 2005

The Journal of Heart and Lung Transplantation

View full text Add to dashboard Cite

Amelioration of microvascular myocardial ischemia by gene transfer of vascular endothelial growth factor in rabbits

Abstract: In vivo vascular endothelial growth factor 165 gene transfer promoted angiogenesis and was an effective approach to treating microvascular myocardial ischemia.

Cited by 22 publications

References 26 publications

Heavy ion radiation up-regulates Cx43 and ameliorates arrhythmogenic substrates in hearts after myocardial infarction

Heavy ion radiation up-regulates Cx43 and ameliorates arrhythmogenic substrates in hearts after myocardial infarction

Early cardiac hypertrophy induced by thyroxine is accompanied by an increase in VEGF-A expression but not by an increase in capillary density

In Vitro Functional Assessment of Human Skeletal Myoblasts After Transduction With Adenoviral Bicistronic Vector Carrying Human VEGF165 and Angiopoietin-1

Contact Info

Product

Resources

About